Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
William J. Gradishar, Meena S. Moran, Jame Abraham, et al.
Journal of the National Comprehensive Cancer Network (2022) Vol. 20, Iss. 6, pp. 691-722
Open Access | Times Cited: 740

Showing 1-25 of 740 citing articles:

Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer
Roberto A. Leon‐Ferre, Sarah Flora Jonas, Roberto Salgado, et al.
JAMA (2024) Vol. 331, Iss. 13, pp. 1135-1135
Closed Access | Times Cited: 64
Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses
William Chen, Abrar Choudhury, Mark W. Youngblood, et al.
Nature Medicine (2023) Vol. 29, Iss. 12, pp. 3067-3076
Open Access | Times Cited: 54
Artificial Intelligence in Breast Cancer Diagnosis and Personalized Medicine
Jong Seok Ahn, Sangwon Shin, Su‐A Yang, et al.
Journal of Breast Cancer (2023) Vol. 26, Iss. 5, pp. 405-405
Open Access | Times Cited: 49
The Role of PET/CT in Breast Cancer
Bawinile Hadebe, Lerwine Harry, Tasmeera Ebrahim, et al.
Diagnostics (2023) Vol. 13, Iss. 4, pp. 597-597
Open Access | Times Cited: 45
Current Treatment Landscape for Early Triple-Negative Breast Cancer (TNBC)
Jieun Lee
Journal of Clinical Medicine (2023) Vol. 12, Iss. 4, pp. 1524-1524
Open Access | Times Cited: 43
A review of the clinical efficacy of FDA-approved antibody‒drug conjugates in human cancers
Kaifeng Liu, Meijia Li, Yudong Li, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 43
Evaluation of AlphaFold structure-based protein stability prediction on missense variations in cancer
Hilal Keskin Karakoyun, Şirin Yüksel, Ilayda Amanoglu, et al.
Frontiers in Genetics (2023) Vol. 14
Open Access | Times Cited: 42
HER2-targeted therapies in cancer: a systematic review
Kunrui Zhu, Xinyi Yang, Hebei Tai, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 27
Liquid biopsy in cancer current: status, challenges and future prospects
Liwei Ma, Huiling Guo, Yunxiang Zhao, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 23
Trends in Guideline-Concordant Care for Inflammatory Breast Cancer
Audree B. Tadros, Brian Diskin, Varadan Sevilimedu, et al.
JAMA Network Open (2025) Vol. 8, Iss. 2, pp. e2454506-e2454506
Open Access | Times Cited: 1
Safety of Targeted Axillary Dissection After Neoadjuvant Therapy in Patients With Node-Positive Breast Cancer
Sherko Kuemmel, Joerg Heil, S. Bruz̆as, et al.
JAMA Surgery (2023) Vol. 158, Iss. 8, pp. 807-807
Closed Access | Times Cited: 37
Postoperative radiotherapy omission in selected patients with early breast cancer following preoperative breast MRI (PROSPECT): primary results of a prospective two-arm study
G. Bruce Mann, Anita Skandarajah, Nicholas Zdenkowski, et al.
The Lancet (2023) Vol. 403, Iss. 10423, pp. 261-270
Closed Access | Times Cited: 33
Impact of 18F-Labeled Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography Versus Conventional Staging in Patients With Locally Advanced Breast Cancer
Ian S. Dayes, Ur Metser, Nicole Hodgson, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 23, pp. 3909-3916
Closed Access | Times Cited: 29
Advances in medical treatment of breast cancer in 2022
Jingtong Zhai, Yun Wu, Fei Ma, et al.
Cancer Innovation (2023) Vol. 2, Iss. 1, pp. 1-17
Open Access | Times Cited: 27
GelMA, Click-Chemistry Gelatin and Bioprinted Polyethylene Glycol-Based Hydrogels as 3D Ex Vivo Drug Testing Platforms for Patient-Derived Breast Cancer Organoids
Nathalie Bock, Farzaneh Forouz, Luke Hipwood, et al.
Pharmaceutics (2023) Vol. 15, Iss. 1, pp. 261-261
Open Access | Times Cited: 25
Genetics of Hepatocellular Carcinoma: From Tumor to Circulating DNA
Claudia Campani, Jessica Zucman‐Rossi, Jean‐Charles Nault
Cancers (2023) Vol. 15, Iss. 3, pp. 817-817
Open Access | Times Cited: 24
Clinical applications of deep learning in breast MRI
Xue Zhao, Jing‐Wen Bai, Qiu Guo, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2023) Vol. 1878, Iss. 2, pp. 188864-188864
Closed Access | Times Cited: 24
CDK4/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective
Fiona H. Zhou, Teesha Downton, Allegra Freelander, et al.
Frontiers in Cell and Developmental Biology (2023) Vol. 11
Open Access | Times Cited: 24
Sentinel Lymph Node Biopsy in Breast Cancer Patients Undergoing Neo-Adjuvant Chemotherapy: Clinical Experience with Node-Negative and Node-Positive Disease Prior to Systemic Therapy
Corrado Tinterri, Andrea Sagona, E. Barbieri, et al.
Cancers (2023) Vol. 15, Iss. 6, pp. 1719-1719
Open Access | Times Cited: 22
Filling the Gap after CDK4/6 Inhibitors: Novel Endocrine and Biologic Treatment Options for Metastatic Hormone Receptor Positive Breast Cancer
Abhenil Mittal, Consolacion Molto Valiente, Faris Tamimi, et al.
Cancers (2023) Vol. 15, Iss. 7, pp. 2015-2015
Open Access | Times Cited: 22
MDSCs in breast cancer: an important enabler of tumor progression and an emerging therapeutic target
Haoyu Liu, Zhicheng Wang, Zhou Yuntao, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 22
Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment
Antonino Glaviano, Seth A. Wander, Richard D. Baird, et al.
Drug Resistance Updates (2024) Vol. 76, pp. 101103-101103
Open Access | Times Cited: 11
ER-Targeted PET for Initial Staging and Suspected Recurrence in ER-Positive Breast Cancer
Gary A. Ulaner, Mel Silverstein, Chaitali Nangia, et al.
JAMA Network Open (2024) Vol. 7, Iss. 7, pp. e2423435-e2423435
Open Access | Times Cited: 10
Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments
Claudia Campani, Sandrine Imbeaud, Gabrielle Couchy, et al.
Gut (2024) Vol. 73, Iss. 11, pp. 1870-1882
Closed Access | Times Cited: 9
The optimal neoadjuvant treatment strategy for HR+/HER2 + breast cancer: a network meta-analysis
Shiwei Liu, Miao Yu, Exian Mou, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top